Finance

Lists
AORT:NYSE
Artivion Inc
$28.08
-1.07%
(-0.31) 1D
Aug 12, 9:54:50 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AORT...
Open
$27.95
High
$28.34
Low
$27.73
Mkt. cap
1.37B
Avg. vol.
647.81K
Volume
30.48K
52-wk high
$48.25
52-wk low
$19.16
EPS
-$0.07
Beta
1.25
Shares outstanding
48.76M
No. of employees
2K
Open
$27.95
High
$28.34
Low
$27.73
Mkt. cap
1.37B
Avg. vol.
647.81K
Volume
30.48K
52-wk high
$48.25
52-wk low
$19.16
EPS
-$0.07
Beta
1.25
Shares outstanding
48.76M
No. of employees
2K
News stories
From web sources and news partners
Profile
Artivion, Inc. is a distributor of cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. Among its products are human heart valves, which are treated to remove excess cellular material and antigens, and BioGlue surgical adhesive. Wikipedia
About Artivion Inc
CEOJames Patrick Mackin
Employees1.8K
Founded1984
HeadquartersKennesaw, Georgia, United States
SectorMedical device
Websiteartivion.com
Analyst ratings
Based on 6 analysts giving stock ratings to AORT in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for AORT in the last 3 months.
Highest
Current $28.08
$45.00 (+60.23%)
Average
$41.70 (+48.48%)
Lowest
$38.00 (+35.30%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jeffrey Cohen
Ladenburg Thalmann & Co.
Buy
Maintained
$39.20
+39.6%
08/07/2026
Frank Takkinen
Lake Street
Buy
Reiterated
$45.00
+60.2%
08/07/2026
Suraj Kalia
Oppenheimer
Buy
Reiterated
$38.00
+35.3%
08/07/2026
Rick Wise
Stifel Nicolaus
Buy
Reiterated
$45.00
+60.2%
08/07/2026
Michael Matson
Needham
Buy
Reiterated
$44.00
+56.7%
08/07/2026
William Plovanic
Canaccord Genuity
Buy
Reiterated
$39.00
+38.9%
08/07/2026
Daniel Stauder
Citizens JMP
Buy
Maintained
$48.00
+70.9%
05/08/2026
Eric Martinuzzi
Lake Street
Buy
Reiterated
$55.00
+95.8%
04/08/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.13 / $0.10
+34.48%beat
Revenue / Est. (USD)
125.76M / 120.01M
+4.79%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
113.39M
115.99M
116.34M
125.76M
Cost of goods sold
38.99M
42.85M
40.89M
45.24M
Cost of revenue
38.99M
42.85M
40.89M
45.24M
Research and development expenses
8.08M
9.12M
8.84M
9.06M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
54.68M
54.64M
60.58M
60.13M
Operating expense
62.76M
63.76M
69.42M
69.18M
Total operating expenses
101.75M
106.61M
110.31M
114.42M
Operating income
11.64M
9.38M
6.03M
11.34M
Other non operating income
499.00K
1.18M
514.00K
-49.00K
EBT including unusual items
7.06M
6.54M
339.00K
-11.70M
EBT excluding unusual items
6.16M
5.15M
579.00K
3.70M
Income tax expense
554.00K
4.11M
-1.08M
1.81M
Effective tax rate
7.85%
62.89%
-317.99%
-15.48%
Other operating expenses
-
-
-
-
Net income
6.50M
2.43M
1.42M
-13.51M
Net profit margin
5.73%
2.09%
1.22%
-10.74%
Earnings per share
0.16
0.17
0.08
0.13
Interest and investment income
240.00K
311.00K
205.00K
367.00K
Interest expense
-6.12M
-5.62M
-5.37M
-7.25M
Net interest expenses
-5.88M
-5.31M
-5.16M
-6.89M
Depreciation and amortization charges
-
-
-
-
EBITDA
17.35M
15.14M
12.37M
18.08M
Gain or loss from assets sale
-3.50M
-3.50M
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps